Breaking News Instant updates and real-time market news.

PRPH

ProPhase Labs

$3.48 /

-0.17 (-4.66%)

17:09
09/30/20
09/30
17:09
09/30/20
17:09

ProPhase to explore CLIA lab acquisition, enters agreement with Predictive Labs

ProPhase Labs announced its intention to explore the acquisition of one or more CLIA, or Clinical Laboratory Improvement Amendment, accredited labs suitable for COVID-19 and other testing. To assist with this process, the company has entered into a consulting agreement with Predictive Laboratories, pursuant to which Predictive Labs has agreed to provide certain consulting and other services to the company, including its assistance in: identifying and introducing the company to new opportunities in the medical technology and testing fields; assisting and advising the company in acquiring one or more CLIA accredited labs suitable for COVID-19 and other testing; obtaining new business for any such labs acquired by the company; equipping and staffing such labs; advising and assisting in the operation of such labs and assisting the company in validating and obtaining certification of such labs. The company has also entered into an amended and restated promissory note and security agreement with predictive labs, pursuant to which the company has loaned to Predictive Labs $3M. All compensation that may be earned by Predictive Labs under the consulting agreement is milestone-based and will first be applied to the acceleration and prepayment of all sums due to the company, including but not limited to sums due pursuant to the new note.

TODAY'S FREE FLY STORIES

Downgrade
Saab downgraded to Hold from Buy at SEB Equities » 05:11
10/20/20
10/20
05:11
10/20/20
05:11
SAABF

Saab

$0.00 /

+ (+0.00%)

SEB Equities analyst Erik…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SAABF Saab
$0.00 /

+ (+0.00%)

06/30/20 Citi
Saab price target lowered to SEK 330 from SEK 390 at Citi
Downgrade
KP Tissue downgraded to Sector Perform from Outperform at RBC Capital » 05:11
10/20/20
10/20
05:11
10/20/20
05:11
KPTSF

KP Tissue

$0.00 /

+ (+0.00%)

RBC Capital analyst Paul…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
KPTSF KP Tissue
$0.00 /

+ (+0.00%)

KPTSF KP Tissue
$0.00 /

+ (+0.00%)

07/09/20 Scotiabank
KP Tissue price target raised to C$12.50 from C$12 at Scotiabank
06/15/20 CIBC
KP Tissue price target raised to C$12 from C$11 at CIBC
05/11/20 TD Securities
KP Tissue price target raised to C$11 from C$10 at TD Securities
03/13/20 RBC Capital
KP Tissue price target raised to C$13 from C$12 at RBC Capital
KPTSF KP Tissue
$0.00 /

+ (+0.00%)

Upgrade
Rayonier Advanced upgraded to Outperform from Sector Perform at RBC Capital » 05:10
10/20/20
10/20
05:10
10/20/20
05:10
RYAM

Rayonier Advanced Materials

$4.12 /

+0.04 (+0.98%)

RBC Capital analyst Paul…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RYAM Rayonier Advanced Materials
$4.12 /

+0.04 (+0.98%)

RYAM Rayonier Advanced Materials
$4.12 /

+0.04 (+0.98%)

06/19/20
Fly Intel: Top five analyst upgrades
06/19/20 BofA
Rayonier Advanced Materials double-upgraded to Buy from Underperform at BofA
06/19/20 BofA
Rayonier Advanced Materials upgraded to Buy from Underperform at BofA
06/05/20
Fly Intel: Top five analyst downgrades
RYAM Rayonier Advanced Materials
$4.12 /

+0.04 (+0.98%)

RYAM Rayonier Advanced Materials
$4.12 /

+0.04 (+0.98%)

Upgrade
James Hardie upgraded to Outperform from Sector Perform at RBC Capital » 05:10
10/20/20
10/20
05:10
10/20/20
05:10
JHX

James Hardie

$25.41 /

-0.36 (-1.40%)

RBC Capital analyst Paul…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
JHX James Hardie
$25.41 /

-0.36 (-1.40%)

JHX James Hardie
$25.41 /

-0.36 (-1.40%)

08/12/20 Citi
James Hardie downgraded to Neutral from Buy at Citi
06/23/20 Jefferies
James Hardie upgraded to Hold from Underperform at Jefferies
06/08/20 Goldman Sachs
James Hardie resumed with a Buy at Goldman Sachs
05/13/20 Credit Suisse
James Hardie upgraded to Outperform from Neutral at Credit Suisse
JHX James Hardie
$25.41 /

-0.36 (-1.40%)

Earnings
Mercantile Bank reports Q3 EPS 66c, consensus 42c » 05:09
10/20/20
10/20
05:09
10/20/20
05:09
MBWM

Mercantile Bank

$21.32 /

+0.12 (+0.57%)

Reports Q3 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MBWM Mercantile Bank
$21.32 /

+0.12 (+0.57%)

Upgrade
J D Wetherspoon upgraded to Buy from Hold at Stifel » 05:08
10/20/20
10/20
05:08
10/20/20
05:08
JDWPF

J D Wetherspoon

$0.00 /

+ (+0.00%)

Stifel analyst Mark…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
JDWPF J D Wetherspoon
$0.00 /

+ (+0.00%)

09/21/20 Morgan Stanley
J D Wetherspoon upgraded to Equal Weight from Underweight at Morgan Stanley
Upgrade
Investor AB upgraded to Buy from Hold at Pareto » 05:06
10/20/20
10/20
05:06
10/20/20
05:06
IVSBF

Investor AB

$0.00 /

+ (+0.00%)

Pareto analyst Herman…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Earnings
Signature Bank reports Q3 EPS 2.62, consensus $2.76 » 05:04
10/20/20
10/20
05:04
10/20/20
05:04
SBNY

Signature Bank

$85.93 /

-0.97 (-1.12%)

Reports Q3 book value per…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SBNY Signature Bank
$85.93 /

-0.97 (-1.12%)

10/09/20 Credit Suisse
Signature Bank initiated with an Outperform at Credit Suisse
10/08/20 Piper Sandler
Signature Bank initiated with an Overweight at Piper Sandler
07/22/20 Wells Fargo
Signature Bank price target raised to $125 from $120 at Wells Fargo
05/28/20 Wedbush
Signature Bank upgraded to Outperform at Wedbush
SBNY Signature Bank
$85.93 /

-0.97 (-1.12%)

Initiation
Entra initiated with a Sell at Pareto » 05:03
10/20/20
10/20
05:03
10/20/20
05:03
ENTOF

Entra

$0.00 /

+ (+0.00%)

Pareto initiated coverage…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Upgrade
Scatec Solar upgraded to Buy from Hold at Kepler Cheuvreux » 05:02
10/20/20
10/20
05:02
10/20/20
05:02
STECF

Scatec Solar

$0.00 /

+ (+0.00%)

Kepler Cheuvreux analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
STECF Scatec Solar
$0.00 /

+ (+0.00%)

10/19/20 Pareto
Scatec Solar upgraded to Hold from Sell at Pareto
10/14/20 DNB Markets
Scatec Solar downgraded to Sell from Hold at DNB Markets
Upgrade
Ipsen upgraded to Hold from Reduce at Kepler Cheuvreux » 05:01
10/20/20
10/20
05:01
10/20/20
05:01
IPSEY

Ipsen

$0.00 /

+ (+0.00%)

Kepler Cheuvreux analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
IPSEY Ipsen
$0.00 /

+ (+0.00%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

09/21/20 Kepler Cheuvreux
Ipsen downgraded to Reduce from Hold at Kepler Cheuvreux
09/01/20 Morgan Stanley
Ipsen price target raised to EUR 101 from EUR 90 at Morgan Stanley
08/26/20 JPMorgan
JPMorgan backs Overweight on Ipsen after palovarotene data
08/04/20 UBS
Ipsen price target raised to EUR 101 from EUR 99 at UBS
Upgrade
Fortinet upgraded to Buy from Neutral at Goldman Sachs » 05:00
10/20/20
10/20
05:00
10/20/20
05:00
FTNT

Fortinet

$128.78 /

-2.81 (-2.14%)

Goldman Sachs analyst…

Goldman Sachs analyst Brian Essex upgraded Fortinet to Buy from Neutral with a price target of $150, up from $143. The stock closed Monday down $2.72 to $128.82. Based on recent conversations with industry participants as well as industry trends this quarter, the analyst believes Fortinet's large enterprise headwinds "may be abating sooner than anticipated." Further, the company's SD-WAN traction still seems to be accelerating and NP7 product cycles remain in early stages, Essex tells investors in a research note. Given its valuation discount to peers, improving execution, product cycle strength and firewall "tailwind," Fortinet is well positioned to outperform from current levels, says the analyst.

ShowHide Related Items >><<
FTNT Fortinet
$128.78 /

-2.81 (-2.14%)

FTNT Fortinet
$128.78 /

-2.81 (-2.14%)

10/15/20 Mizuho
Fortinet price target raised to $130 from $123 at Mizuho
08/26/20 UBS
Fortinet price target raised to $140 from $134 at UBS
08/20/20 Deutsche Bank
Fortinet initiated with a Hold at Deutsche Bank
08/07/20 UBS
Fortinet price target raised to $134 from $122 at UBS
FTNT Fortinet
$128.78 /

-2.81 (-2.14%)

FTNT Fortinet
$128.78 /

-2.81 (-2.14%)

FTNT Fortinet
$128.78 /

-2.81 (-2.14%)

FTNT Fortinet
$128.78 /

-2.81 (-2.14%)

Initiation
PMV Pharmaceuticals initiated with a Neutral at Goldman Sachs » 04:57
10/20/20
10/20
04:57
10/20/20
04:57
PMVP

PMV Pharmaceuticals

$37.84 /

+1.58 (+4.36%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PMVP PMV Pharmaceuticals
$37.84 /

+1.58 (+4.36%)

  • 25
    Sep
PMVP PMV Pharmaceuticals
$37.84 /

+1.58 (+4.36%)

Initiation
Prelude Therapeutics initiated with a Neutral at Goldman Sachs » 04:56
10/20/20
10/20
04:56
10/20/20
04:56
PRLD

Prelude Therapeutics

$32.96 /

+1.36 (+4.30%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PRLD Prelude Therapeutics
$32.96 /

+1.36 (+4.30%)

  • 25
    Sep
PRLD Prelude Therapeutics
$32.96 /

+1.36 (+4.30%)

Conference/Events
Roth Capital alternative energy analysts hold analyst/industry conference call » 04:55
10/20/20
10/20
04:55
10/20/20
04:55
ENPH

Enphase Energy

$114.57 /

+3.71 (+3.35%)

, SEDG

SolarEdge

$308.80 /

+6.62 (+2.19%)

, GNRC

Generac

$210.06 /

+1.89 (+0.91%)

, NOVA

Sunnova Energy

$29.95 /

+0.88 (+3.03%)

, RUN

Sunrun

$62.33 /

-0.09 (-0.14%)

, SPWR

SunPower

$17.49 /

+0.51 (+3.00%)

Alternative Energy…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ENPH Enphase Energy
$114.57 /

+3.71 (+3.35%)

SEDG SolarEdge
$308.80 /

+6.62 (+2.19%)

GNRC Generac
$210.06 /

+1.89 (+0.91%)

NOVA Sunnova Energy
$29.95 /

+0.88 (+3.03%)

RUN Sunrun
$62.33 /

-0.09 (-0.14%)

SPWR SunPower
$17.49 /

+0.51 (+3.00%)

ENPH Enphase Energy
$114.57 /

+3.71 (+3.35%)

10/15/20 Susquehanna
Susquehanna upgrades Enphase Energy on residential growth potential
10/15/20 Susquehanna
Enphase Energy initiated with a Positive at Susquehanna
10/01/20 BofA
Enphase Energy initiated with a Buy at BofA
10/01/20 BofA
Enphase Energy initiated with a Buy at BofA
SEDG SolarEdge
$308.80 /

+6.62 (+2.19%)

10/15/20 Goldman Sachs
SolarEdge upgraded to Neutral from Sell at Goldman Sachs
10/15/20 Susquehanna
SolarEdge initiated with a Positive at Susquehanna
09/30/20 JPMorgan
SolarEdge price target raised to $252 from $222 at JPMorgan
09/23/20 B. Riley FBR
SolarEdge initiated with a Buy at B. Riley FBR
GNRC Generac
$210.06 /

+1.89 (+0.91%)

10/16/20 Stephens
Generac initiated with an Overweight at Stephens
10/15/20 Canaccord
Generac price target raised to $250 from $200 at Canaccord
10/14/20 JMP Securities
Sunnova Energy price target raised to $55 from $43 at JMP Securities
10/07/20 Oppenheimer
Generac price target raised to $225 from $175 at Oppenheimer
NOVA Sunnova Energy
$29.95 /

+0.88 (+3.03%)

10/14/20 JMP Securities
Sunnova Energy price target raised to $55 from $43 at JMP Securities
10/07/20 Piper Sandler
Sunnova Energy initiated with an Overweight at Piper Sandler
09/30/20 JPMorgan
Sunnova Energy assumed with an Overweight at JPMorgan
09/30/20 Roth Capital
Short report on Sunnova Energy 'misses the mark,' says Roth Capital
RUN Sunrun
$62.33 /

-0.09 (-0.14%)

10/07/20 Piper Sandler
Sunrun initiated with a Neutral at Piper Sandler
10/06/20 GLJ Research
SunPower upgraded to Buy from Sell at GLJ Research
09/30/20
Fly Intel: Top five analyst downgrades
09/30/20 JPMorgan
Sunrun price target raised to $79 from $61 at JPMorgan
SPWR SunPower
$17.49 /

+0.51 (+3.00%)

10/07/20
Fly Intel: Top five analyst initiations
10/07/20 Piper Sandler
SunPower initiated with an Overweight at Piper Sandler
10/06/20 GLJ Research
SunPower upgraded to Buy from Sell at GLJ Research
09/30/20 JPMorgan
SunPower price target raised to $13 from $11 at JPMorgan
ENPH Enphase Energy
$114.57 /

+3.71 (+3.35%)

SEDG SolarEdge
$308.80 /

+6.62 (+2.19%)

GNRC Generac
$210.06 /

+1.89 (+0.91%)

NOVA Sunnova Energy
$29.95 /

+0.88 (+3.03%)

RUN Sunrun
$62.33 /

-0.09 (-0.14%)

SPWR SunPower
$17.49 /

+0.51 (+3.00%)

  • 13
    Oct
  • 14
    Aug
  • 01
    Jul
  • 21
    Nov
ENPH Enphase Energy
$114.57 /

+3.71 (+3.35%)

ENPH Enphase Energy
$114.57 /

+3.71 (+3.35%)

SEDG SolarEdge
$308.80 /

+6.62 (+2.19%)

NOVA Sunnova Energy
$29.95 /

+0.88 (+3.03%)

RUN Sunrun
$62.33 /

-0.09 (-0.14%)

SPWR SunPower
$17.49 /

+0.51 (+3.00%)

ENPH Enphase Energy
$114.57 /

+3.71 (+3.35%)

SEDG SolarEdge
$308.80 /

+6.62 (+2.19%)

NOVA Sunnova Energy
$29.95 /

+0.88 (+3.03%)

RUN Sunrun
$62.33 /

-0.09 (-0.14%)

SPWR SunPower
$17.49 /

+0.51 (+3.00%)

Conference/Events
HealthEquity management to meet virtually with KeyBanc » 04:55
10/20/20
10/20
04:55
10/20/20
04:55
HQY

HealthEquity

$52.07 /

-2.24 (-4.12%)

Virtual Meeting to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
HQY HealthEquity
$52.07 /

-2.24 (-4.12%)

HQY HealthEquity
$52.07 /

-2.24 (-4.12%)

09/10/20 Deutsche Bank
HealthEquity price target raised to $60 from $57 at Deutsche Bank
09/09/20 Barrington
HealthEquity price target raised to $70 from $65 at Barrington
09/09/20 SVB Leerink
HealthEquity price target raised to $64 from $51 at SVB Leerink
09/09/20 Wells Fargo
HealthEquity price target raised to $70 from $63 at Wells Fargo
HQY HealthEquity
$52.07 /

-2.24 (-4.12%)

  • 09
    Jul
HQY HealthEquity
$52.07 /

-2.24 (-4.12%)

HQY HealthEquity
$52.07 /

-2.24 (-4.12%)

Conference/Events
Lennar management to meet virtually with BTIG » 04:55
10/20/20
10/20
04:55
10/20/20
04:55
LEN

Lennar

$82.57 /

-2.08 (-2.46%)

Virtual Meeting to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
LEN Lennar
$82.57 /

-2.08 (-2.46%)

LEN Lennar
$82.57 /

-2.08 (-2.46%)

10/13/20 Zelman
TRI Pointe added to Top Idea Basket at Zelman
10/08/20 JPMorgan
Lennar price target raised to $94 from $87 at JPMorgan
09/17/20
Fly Intel: Top five analyst upgrades
09/17/20 Citi
Citi boosts Lennar target to $90, says post-earnings selloff overdone
LEN Lennar
$82.57 /

-2.08 (-2.46%)

LEN Lennar
$82.57 /

-2.08 (-2.46%)

LEN Lennar
$82.57 /

-2.08 (-2.46%)

LEN Lennar
$82.57 /

-2.08 (-2.46%)

General news
Week of 10/17 Redbook to be released at 08:55  04:55
10/20/20
10/20
04:55
10/20/20
04:55
 
General news
4-Week Bill Announcement to be released at 11:00  04:55
10/20/20
10/20
04:55
10/20/20
04:55
 
Conference/Events
Frequency Therapeutics management to meet virtually with Oppenheimer » 04:55
10/20/20
10/20
04:55
10/20/20
04:55
FREQ

Frequency Therapeutics

$21.32 /

-0.82 (-3.70%)

Virtual Meetings to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FREQ Frequency Therapeutics
$21.32 /

-0.82 (-3.70%)

FREQ Frequency Therapeutics
$21.32 /

-0.82 (-3.70%)

07/13/20 Oppenheimer
Frequency Therapeutics initiated with an Outperform at Oppenheimer
05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
FREQ Frequency Therapeutics
$21.32 /

-0.82 (-3.70%)

FREQ Frequency Therapeutics
$21.32 /

-0.82 (-3.70%)

FREQ Frequency Therapeutics
$21.32 /

-0.82 (-3.70%)

Conference/Events
Collegium Pharmaceutical management to meet virtually with Gabelli » 04:55
10/20/20
10/20
04:55
10/20/20
04:55
COLL

Collegium Pharmaceutical

$20.36 /

-0.4 (-1.93%)

Virtual Meeting to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
COLL Collegium Pharmaceutical
$20.36 /

-0.4 (-1.93%)

COLL Collegium Pharmaceutical
$20.36 /

-0.4 (-1.93%)

07/14/20 BWS Financial
Collegium Pharmaceutical initiated with a Sell at BWS Financial
05/27/20 Guggenheim
Guggenheim starts coverage of four pain treatment makers with two Buys
05/26/20 Guggenheim
Collegium Pharmaceutical initiated with a Neutral at Guggenheim
03/23/20 SunTrust
SunTrust lowers price targets among Pharmaceuticals due to COVID-19
COLL Collegium Pharmaceutical
$20.36 /

-0.4 (-1.93%)

Conference/Events
Abiomed to ho ld a conference call » 04:55
10/20/20
10/20
04:55
10/20/20
04:55
ABMD

Abiomed

$281.11 /

-5.62 (-1.96%)

Management discusses the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ABMD Abiomed
$281.11 /

-5.62 (-1.96%)

ABMD Abiomed
$281.11 /

-5.62 (-1.96%)

08/07/20 SVB Leerink
Abiomed price target raised to $335 from $280 at SVB Leerink
07/13/20 OTR Global
Abiomed upgraded to Positive from Mixed at OTR Global
05/28/20 SVB Leerink
Abiomed price target raised to $225 from $195 at SVB Leerink
05/27/20 Piper Sandler
Abiomed investor meeting offered positive data points, says Piper Sandler
ABMD Abiomed
$281.11 /

-5.62 (-1.96%)

Conference/Events
American Society of Nephrology to hold virtual annual meeting » 04:55
10/20/20
10/20
04:55
10/20/20
04:55
AKBA

Akebia

$3.70 /

-0.06 (-1.60%)

, ALNY

Alnylam

$140.59 /

-4.81 (-3.31%)

, ALPMY

Astellas Pharma

$0.00 /

+ (+0.00%)

, AMGN

Amgen

$230.88 /

-4.99 (-2.12%)

, AZN

AstraZeneca

$52.44 /

-0.58 (-1.09%)

, BAX

Baxter

$81.20 /

-0.62 (-0.76%)

, BAYRY

Bayer

$0.00 /

+ (+0.00%)

, BD

Budget Group

$0.00 /

+ (+0.00%)

, CALT

Calliditas Therapeutics

$27.63 /

-1.17 (-4.06%)

, ICUI

ICU Medical

$191.23 /

-7.85 (-3.94%)

, TCDA

Tricida

$9.01 /

-0.145 (-1.58%)

, SNY

Sanofi

$50.17 /

-0.14 (-0.28%)

, GSK

GlaxoSmithKline

$36.18 /

-0.41 (-1.12%)

, FOLD

Amicus

$16.85 /

-0.35 (-2.03%)

, FMS

Fresenius Medical

$41.47 /

-0.45 (-1.07%)

, DRNA

Dicerna

$20.07 /

-0.4 (-1.95%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, CCXI

ChemoCentryx

$53.65 /

-3.155 (-5.55%)

, KDNY

Chinook Therapeutics

$16.16 /

-0.39 (-2.36%)

, RTRX

Retrophin

$21.34 /

-0.59 (-2.69%)

, OMER

Omeros

$11.08 /

-0.4 (-3.48%)

, OM

Outset Medical

$47.68 /

-0.66 (-1.37%)

, NVS

Novartis

$85.77 /

-0.44 (-0.51%)

, VRTX

Vertex Pharmaceuticals

$220.71 /

+2.65 (+1.22%)

Kidney Week 2020: Virtual…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AKBA Akebia
$3.70 /

-0.06 (-1.60%)

ALNY Alnylam
$140.59 /

-4.81 (-3.31%)

ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

AMGN Amgen
$230.88 /

-4.99 (-2.12%)

AZN AstraZeneca
$52.44 /

-0.58 (-1.09%)

BAX Baxter
$81.20 /

-0.62 (-0.76%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

ICUI ICU Medical
$191.23 /

-7.85 (-3.94%)

TCDA Tricida
$9.01 /

-0.145 (-1.58%)

SNY Sanofi
$50.17 /

-0.14 (-0.28%)

GSK GlaxoSmithKline
$36.18 /

-0.41 (-1.12%)

FOLD Amicus
$16.85 /

-0.35 (-2.03%)

FMS Fresenius Medical
$41.47 /

-0.45 (-1.07%)

DRNA Dicerna
$20.07 /

-0.4 (-1.95%)

CCXI ChemoCentryx
$53.65 /

-3.155 (-5.55%)

KDNY Chinook Therapeutics
$16.16 /

-0.39 (-2.36%)

RTRX Retrophin
$21.34 /

-0.59 (-2.69%)

OMER Omeros
$11.08 /

-0.4 (-3.48%)

NVS Novartis
$85.77 /

-0.44 (-0.51%)

VRTX Vertex Pharmaceuticals
$220.71 /

+2.65 (+1.22%)

AKBA Akebia
$3.70 /

-0.06 (-1.60%)

09/04/20 RBC Capital
Akebia price target lowered to $5 from $12 at RBC Capital
09/04/20 Stifel
FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel
09/04/20 BTIG
Akebia price target lowered to $6 from $26 at BTIG
09/04/20 Mizuho
Akebia price target lowered to $6 from $17 at Mizuho
ALNY Alnylam
$140.59 /

-4.81 (-3.31%)

09/30/20 Berenberg
Alnylam reinitiated with a Hold at Berenberg
09/08/20 Citi
Alnylam initiated with a Buy at Citi
08/11/20 Oppenheimer
Alnylam downgraded to Perform on valuation at Oppenheimer
08/11/20 Oppenheimer
Alnylam downgraded to Perform from Outperform at Oppenheimer
ALPMY Astellas Pharma
$0.00 /

+ (+0.00%)

10/13/20 JMP Securities
Seagen price target raised to $216 from $200 at JMP Securities
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy on raised PADCEV estimates at Goldman Sachs
05/26/20 Goldman Sachs
Astellas Pharma upgraded to Buy from Neutral at Goldman Sachs
01/23/20 Morgan Stanley
Astellas Pharma resumed with an Overweight at Morgan Stanley
AMGN Amgen
$230.88 /

-4.99 (-2.12%)

10/09/20
Fly Intel: Top five analyst downgrades
10/09/20 Truist
Amgen downgraded to Hold from Buy at Truist
10/09/20 Bernstein
Amgen downgraded to Market Perform from Outperform at Bernstein
10/09/20 Bernstein
Amgen downgraded to Market Perform from Outperform at Bernstein
AZN AstraZeneca
$52.44 /

-0.58 (-1.09%)

10/08/20 JPMorgan
AstraZeneca FY20 guide could look conservative after Q3 results, says JPMorgan
10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
09/29/20 Berenberg
AstraZeneca initiated with a Buy at Berenberg
09/28/20 Maxim
Maxim upgrades Inovio to Buy, says shares oversold after vaccine 'speed bump'
BAX Baxter
$81.20 /

-0.62 (-0.76%)

10/08/20 Goldman Sachs
Baxter pump delays speak more to FDA protocols than actual product, says Goldman
10/08/20 Piper Sandler
Baxter 510k submission withdrawal 'disappointing,' 'not surprising,' says Piper
10/08/20 KeyBanc
Investors will view Baxter pump news 'somewhat negatively,' says KeyBanc
10/01/20
Fly Intel: Top five analyst upgrades
BAYRY Bayer
$0.00 /

+ (+0.00%)

10/13/20 Barclays
Bayer downgraded to Equal Weight from Overweight at Barclays
10/08/20 Kepler Cheuvreux
Bayer upgraded to Buy from Hold at Kepler Cheuvreux
10/05/20 UBS
Bayer price target lowered to EUR 85 from EUR 110 at UBS
10/02/20 Deutsche Bank
Bayer price target lowered to EUR 64 from EUR 82 at Deutsche Bank
BD Budget Group
$0.00 /

+ (+0.00%)

CALT Calliditas Therapeutics
$27.63 /

-1.17 (-4.06%)

07/01/20 Citi
Calliditas Therapeutics initiated with a Buy at Citi
06/30/20 Jefferies
Calliditas Therapeutics initiated with a Buy at Jefferies
06/30/20 Stifel
Calliditas Therapeutics initiated with a Buy at Stifel
ICUI ICU Medical
$191.23 /

-7.85 (-3.94%)

09/02/20 KeyBanc
ICU Medical price target raised to $218 from $199 at KeyBanc
05/13/20 KeyBanc
ICU Medical price target lowered to $199 from $206 at KeyBanc
03/18/20 KeyBanc
ICU Medical upgraded to Overweight from Sector Weight at KeyBanc
11/12/19 Raymond James
ICU Medical price target raised to $203 from $185 at Raymond James
TCDA Tricida
$9.01 /

-0.145 (-1.58%)

09/29/20 JPMorgan
Tricida resumed with an Underweight at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Needham
Tricida price target lowered to $20 from $44 at Needham
08/25/20 Goldman Sachs
Tricida downgraded to Neutral from Buy at Goldman Sachs
SNY Sanofi
$50.17 /

-0.14 (-0.28%)

10/06/20 Raymond James
Raymond James says FDA guidance 'likely assures' no vaccine EUA before late Nov.
10/04/20 Goldman Sachs
Translate Bio initiated with a Buy at Goldman Sachs
09/29/20 Berenberg
Sanofi initiated with a Hold at Berenberg
09/21/20 Piper Sandler
Regeneron's Libtayo delivered results on par with Keytruda, says Piper Sandler
GSK GlaxoSmithKline
$36.18 /

-0.41 (-1.12%)

10/15/20 SVB Leerink
SVB Leerink sees possible opportunity for Amarin to 'salvage Vascepa' in U.S.
10/12/20 UBS
GlaxoSmithKline price target lowered to 1,730 GBp from 1,800 GBp at UBS
10/09/20 Morgan Stanley
GlaxoSmithKline price target lowered to 1,695 GBp from 1,700 GBp at Morgan Stanley
10/08/20 JPMorgan
JPMorgan backs Neutral on GSK ahead of Q3 results
FOLD Amicus
$16.85 /

-0.35 (-2.03%)

08/11/20 Citi
Amicus price target raised to $20 from $15 at Citi
06/16/20 BTIG
Amicus initiated with a Buy at BTIG
06/16/20 H.C. Wainwright
Amicus has positive read from Sanofi COMET data, says H.C. Wainwright
06/09/20 Citi
Amicus shares worth $10 on Galafold alone, says Citi
FMS Fresenius Medical
$41.47 /

-0.45 (-1.07%)

10/13/20 Deutsche Bank
Fresenius Medical price target lowered to EUR 97 from EUR 100 at Deutsche Bank
08/18/20 Morgan Stanley
Fresenius Medical price target raised to EUR 76 from EUR 70 at Morgan Stanley
08/05/20 Jefferies
Fresenius Medical downgraded to Hold from Buy at Jefferies
07/28/20 Berenberg
Fresenius Medical price target raised to EUR 94.85 from EUR 88.25 at Berenberg
DRNA Dicerna
$20.07 /

-0.4 (-1.95%)

08/07/20 H.C. Wainwright
Dicerna price target raised to $35 from $32 at H.C. Wainwright
07/01/20 Baird
Dicerna elevated to Fresh Pick at Baird
05/12/20 RBC Capital
Dicerna initiated with an Outperform at RBC Capital
05/11/20 SunTrust
Dicerna price target raised to $33 from $28 at SunTrust
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

CCXI ChemoCentryx
$53.65 /

-3.155 (-5.55%)

09/17/20 H.C. Wainwright
ChemoCentryx price target raised to $85 from $73 at H.C. Wainwright
09/17/20 Piper Sandler
ChemoCentryx target lowered to $67 at Piper Sandler on lower avacopan AAV sales
08/12/20 SVB Leerink
ChemoCentryx price target raised to $75 from $65 at SVB Leerink
07/09/20 Piper Sandler
ChemoCentryx submits NDA for avacopan in AAV to FDA, says Piper Sandler
KDNY Chinook Therapeutics
$16.16 /

-0.39 (-2.36%)

10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
10/07/20 SVB Leerink
Chinook Therapeutics initiated with an Outperform at SVB Leerink
RTRX Retrophin
$21.34 /

-0.59 (-2.69%)

09/17/20 Wedbush
Wedbush starts Retrophin at Outperform ahead of 'value-creating catalysts'
09/17/20 Wedbush
Retrophin initiated with an Outperform at Wedbush
08/24/20 BofA
Retrophin initiated with a Buy at BofA
07/13/20 BMO Capital
Retrophin price target lowered to $31 from $34 at BMO Capital
OMER Omeros
$11.08 /

-0.4 (-3.48%)

09/01/20 Wedbush
Omeros price target lowered to $12 from $17 at Wedbush
08/21/20 H.C. Wainwright
Omeros price target lowered to $32 from $34 at H.C. Wainwright
03/04/20 Wedbush
Omeros price target raised to $22 from $18 at Wedbush
03/03/20 Cantor Fitzgerald
Omeros shares can 'significantly rerate' from here, says Cantor Fitzgerald
OM Outset Medical
$47.68 /

-0.66 (-1.37%)

10/12/20
Fly Intel: Top five analyst initiations
10/12/20 Morgan Stanley
Outset Medical initiated with an Equal Weight at Morgan Stanley
10/12/20 Stifel
Outset Medical initiated with a Buy at Stifel
10/12/20 SVB Leerink
Outset Medical initiated with a Market Perform at SVB Leerink
NVS Novartis
$85.77 /

-0.44 (-0.51%)

09/29/20 Berenberg
Novartis initiated with a Buy at Berenberg
09/24/20 Barclays
Regenxbio price target lowered to $79 from $88 at Barclays
09/23/20 BMO Capital
Ionis Pharmaceuticals' Spinraza benefits from Novartis' AVXS-101 delay, says BMO
09/23/20 SVB Leerink
Ionis should trade up, Regenxbio down after Novartis update, says SVB Leerink
VRTX Vertex Pharmaceuticals
$220.71 /

+2.65 (+1.22%)

10/15/20 Truist
Vertex Pharmaceuticals price target lowered to $305 from $330 at Truist
10/15/20 Morgan Stanley
VX-814 discontinuation can drive Vertex shares 5%-10% lower, says Morgan Stanley
10/15/20 JPMorgan
Vertex pipeline setback a 'major disappointment,' says JPMorgan
10/15/20 Citi
Vertex selloff on VX-814 news a buying opportunity, says Citi
AKBA Akebia
$3.70 /

-0.06 (-1.60%)

ALNY Alnylam
$140.59 /

-4.81 (-3.31%)

AMGN Amgen
$230.88 /

-4.99 (-2.12%)

AZN AstraZeneca
$52.44 /

-0.58 (-1.09%)

BAX Baxter
$81.20 /

-0.62 (-0.76%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

ICUI ICU Medical
$191.23 /

-7.85 (-3.94%)

TCDA Tricida
$9.01 /

-0.145 (-1.58%)

SNY Sanofi
$50.17 /

-0.14 (-0.28%)

GSK GlaxoSmithKline
$36.18 /

-0.41 (-1.12%)

FOLD Amicus
$16.85 /

-0.35 (-2.03%)

DRNA Dicerna
$20.07 /

-0.4 (-1.95%)

CCXI ChemoCentryx
$53.65 /

-3.155 (-5.55%)

RTRX Retrophin
$21.34 /

-0.59 (-2.69%)

OMER Omeros
$11.08 /

-0.4 (-3.48%)

NVS Novartis
$85.77 /

-0.44 (-0.51%)

VRTX Vertex Pharmaceuticals
$220.71 /

+2.65 (+1.22%)

  • 15
    Sep
  • 12
    Aug
  • 11
    Jun
  • 09
    Jun
  • 05
    Jun
  • 12
    May
  • 05
    Dec
AKBA Akebia
$3.70 /

-0.06 (-1.60%)

AMGN Amgen
$230.88 /

-4.99 (-2.12%)

AZN AstraZeneca
$52.44 /

-0.58 (-1.09%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

SNY Sanofi
$50.17 /

-0.14 (-0.28%)

GSK GlaxoSmithKline
$36.18 /

-0.41 (-1.12%)

FOLD Amicus
$16.85 /

-0.35 (-2.03%)

NVS Novartis
$85.77 /

-0.44 (-0.51%)

VRTX Vertex Pharmaceuticals
$220.71 /

+2.65 (+1.22%)

AKBA Akebia
$3.70 /

-0.06 (-1.60%)

ALNY Alnylam
$140.59 /

-4.81 (-3.31%)

AMGN Amgen
$230.88 /

-4.99 (-2.12%)

AZN AstraZeneca
$52.44 /

-0.58 (-1.09%)

BAX Baxter
$81.20 /

-0.62 (-0.76%)

BAYRY Bayer
$0.00 /

+ (+0.00%)

CALT Calliditas Therapeutics
$27.63 /

-1.17 (-4.06%)

ICUI ICU Medical
$191.23 /

-7.85 (-3.94%)

TCDA Tricida
$9.01 /

-0.145 (-1.58%)

SNY Sanofi
$50.17 /

-0.14 (-0.28%)

GSK GlaxoSmithKline
$36.18 /

-0.41 (-1.12%)

CCXI ChemoCentryx
$53.65 /

-3.155 (-5.55%)

OMER Omeros
$11.08 /

-0.4 (-3.48%)

OM Outset Medical
$47.68 /

-0.66 (-1.37%)

NVS Novartis
$85.77 /

-0.44 (-0.51%)

VRTX Vertex Pharmaceuticals
$220.71 /

+2.65 (+1.22%)

AKBA Akebia
$3.70 /

-0.06 (-1.60%)

AMGN Amgen
$230.88 /

-4.99 (-2.12%)

AZN AstraZeneca
$52.44 /

-0.58 (-1.09%)

SNY Sanofi
$50.17 /

-0.14 (-0.28%)

GSK GlaxoSmithKline
$36.18 /

-0.41 (-1.12%)

KDNY Chinook Therapeutics
$16.16 /

-0.39 (-2.36%)

VRTX Vertex Pharmaceuticals
$220.71 /

+2.65 (+1.22%)

Conference/Events
American Bankers Association to hold virtual convention » 04:55
10/20/20
10/20
04:55
10/20/20
04:55
OCFC

OceanFirst Financial

$15.18 /

+0.09 (+0.60%)

The ABA Unconventional…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OCFC OceanFirst Financial
$15.18 /

+0.09 (+0.60%)

OCFC OceanFirst Financial
$15.18 /

+0.09 (+0.60%)

04/30/20 Stephens
OceanFirst Financial upgraded to Overweight after earnings at Stephens
04/30/20 Stephens
OceanFirst Financial upgraded to Overweight from Equal Weight at Stephens
04/01/20 Keefe Bruyette
OceanFirst Financial upgraded to Outperform from Market Perform at Keefe Bruyette
10/29/19 Stephens
OceanFirst Financial initiated with an Equal Weight at Stephens
OCFC OceanFirst Financial
$15.18 /

+0.09 (+0.60%)

Conference/Events
Kinross Gold to hold a conference call » 04:55
10/20/20
10/20
04:55
10/20/20
04:55
KGC

Kinross Gold

$8.89 /

-0.22 (-2.41%)

Management discusses…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
KGC Kinross Gold
$8.89 /

-0.22 (-2.41%)

KGC Kinross Gold
$8.89 /

-0.22 (-2.41%)

09/21/20 Raymond James
Kinross Gold price target raised to $12 from $10.50 at Raymond James
09/18/20 Canaccord
Kinross Gold free cash flow profile confirmed by guidance, says Canaccord
09/17/20 BMO Capital
Kinross Gold upgraded to Outperform from Market Perform at BMO Capital
09/11/20 National Bank
Kinross Gold price target raised to C$17 from C$16 at National Bank
KGC Kinross Gold
$8.89 /

-0.22 (-2.41%)

KGC Kinross Gold
$8.89 /

-0.22 (-2.41%)

KGC Kinross Gold
$8.89 /

-0.22 (-2.41%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.